iTeos Therapeutics to Present Data from First- in-Human Study of A2A Receptor Antagonist at AACR Virtual Annual Meeting 2020
Gosselies, Belgium and Cambridge, MA – April 20, 2020. iTeos Therapeutics, a privately-held biotechnology company developing novel cancer immunotherapies, announces today that it will present initial data on the first-in-human study of its highly innovative and differentiated A2A receptor antagonist, EOS-850 in a virtual poster presentation at the upcoming American Association of Cancer Research (AACR) Virtual Annual Meeting 2020, taking place April 27-28th.
The abstract and video presentation details are as follows:
Title: First in human study with EOS100850, a novel potent A2A antagonist, shows excellent tolerance and clinical benefit in immune resistant advanced cancers (CT152)
Session: Phase I Clinical Trials
Abstract #: 10228
Authors: Laurence Buisseret, et al.
The video presentation and full abstract will be available on the AACR conference website from 9:00 AM ET on Monday, April 27th.
For further information, please contact:
Michel Detheux, CEO
iTeos Therapeutics SA
Amber Fennell, Paul Kidwell, Matthew Neal and Sukaina Virji
Consilium Strategic Communications
+44 203 709 5700
Sarah McCabe and Zofia Mita
Stern Investor Relations, Inc.
+ 1 212 362 1200